Biogen to pay $1.25bn to Forward Pharma in licensing deal
19-01-2017
Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Forward Pharma, PTAB, Biogen, patent, US Court of Appeals for the Federal Circuit, multiple sclerosis, patent infringement, Kyle Bass
